| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1bceb71676971f1383ae2a7e5ccaa7da |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H05K999-99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2013-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d432b02b908cdc98ae50c07cae9ce785 |
| publicationDate |
2021-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2836424-T3 |
| titleOfInvention |
Antiandrogens to treat castration-resistant and non-metastatic prostate cancer |
| abstract |
A therapeutically effective amount of an antiandrogen that is used in a method of treating castration resistant, non-metastatic prostate cancer in a human male, such that said method includes administering said antiandrogen to a human male with cancer of non-metastatic and castration-resistant prostate, so the antiandrogen is 4- [7- (6-cyano-5-trifluoromethylpyridin-3-yl) -8-oxo-6-thioxo-5,7-diazaspiro [3.4] oct-5-yl] -2-fluoro-N-methylbenzamide, so that the aforementioned method also includes maintaining castrated levels of testosterone by co-administration of a gonadotropin-releasing hormone (GnRH) agonist or antagonist or by orchiectomy , and so that the treatment provides a PSA90 at three months, a PSA50 at six months and / or a PSA90 at six months. |
| priorityDate |
2012-09-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |